口服CXCR4抑制剂X4-136同步放化疗提高宫颈癌肿瘤控制并降低毒性
本研究利用源自患者宫颈癌的原位异种移植模型,评估放疗联合顺铂(RTCT)加口服CXCR4抑制剂X4-136的疗效与毒性。结果显示X4-136可逆转RTCT诱导的CXCL12/CXCR4信号、髓系细胞聚集和PD-L1表达,改善原发肿瘤反应并减少转移,同时减轻肠道急性和晚期放射性损伤。
要点
- X4-136联合RTCT改善宫颈癌原发肿瘤控制并减少淋巴结转移。
- X4-136减轻RTCT相关肠道急性及晚期放射性损伤。
- 该组合拓展了放疗治疗窗,值得开展临床试验。
核心结论
- RTCT联合CXCR4抑制剂X4-136可改善宫颈癌原发肿瘤控制、减少淋巴结转移,并减轻肠道正常组织损伤。
研究设计与样本
- 研究采用源自患者的宫颈癌原位异种移植模型,RT为30 Gy(2 Gy/d),顺铂4 mg/kg/wk腹腔注射,联合或不联合X4-136 100 mg/kg/d口服,持续3周。
主要发现
- 单纯RTCT增加CXCL12/CXCR4信号、瘤内髓系细胞聚集和PD-L1表达,加用X4-136可消除这些效应。
- 加用X4-136改善原发肿瘤反应并减少转移。
- X4-136增加照射后存活肠隐窝细胞比例,并减少晚期放射性组织学改变。
临床怎么用
- 该组合策略在临床前模型中拓展了放疗治疗窗,支持在宫颈癌中开展临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cervical cancer is a global health problem. Despite the growth of prevention programs, there is an important need to improve the effectiveness of treatment for patients with invasive, locally advanced disease. In this study we examined (1) the efficacy of radiation therapy (RT) with cisplatin (RTCT) and an orally administered CXCR4 inhibitor suitable for clinical use, X4-136; (2) biomarkers of response to RTCT and X4-136; and (3) intestinal toxicity from RTCT and X4-136. METHODS AND MATERIALS: Orthotopic cervical cancer xenografts derived from our patients were treated with RT (30 Gy; 2 Gy/d) and cisplatin (4 mg/kg/wk intraperitoneally) with or without concurrent X4-136 (100 mg/kg/d orally) for 3 weeks. Mice were euthanized immediately after treatment for biomarker assessment or followed to evaluate primary tumor growth delay and metastases. In separate experiments, acute and late intestinal injury were assessed histologically. RESULTS: RTCT alone increased CXCL12/CXCR4 signaling, intratumoral accumulation of myeloid cells, and PD-L1 expression. The addition of X4-136 during RTCT abrogated these effects, improved primary tumor response, and reduced metastases. Furthermore, X4-136 increased the proportion of surviving intestinal crypt cells after irradiation, in keeping with a reduction in acute RT toxicity, and reduced late histologic changes of late RT toxicity. CONCLUSIONS: The combination of RTCT and the CXCR4 inhibitor X4-136 improves cervical cancer primary tumor control and reduces lymph node metastases, while also reducing normal tissue injury associated with adverse intestinal effects. Few if any pharmacologic strategies have expanded the therapeutic window with RT, suggesting that this combination warrants testing in clinical trials. These benefits might apply to other tumors where RTCT plays a curative role.
引用
- Chaudary N, Hill RP, Stulik L, et al. The Oral CXCR4 Inhibitor X4-136 Improves Tumor Control and Reduces Toxicity in Cervical Cancer Treated With Radiation Therapy and Concurrent Chemotherapy. Int J Radiat Oncol Biol Phys. 2021. PMID: 33771702. doi:10.1016/j.ijrobp.2021.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。